Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity

Cancer Research

Volumn 64, Issue 23, 2004, Pages 8754-8760

  Suzuki, Yoshinori ^a,b   Wakita, Daiko ^a   Chamoto, Kenji ^a   Narita, Yoshinori ^a   Tsuji, Takemasa ^a   Takeshima, Tsuguhide ^a   Gyobu, Hiroshi ^a,b   Kawarada, You ^b   Kondo, Satoshi ^b   Akira, Shizuo ^c   Katoh, Hiroyuki ^b   Ikeda, Hiroaki ^a   Nishimura, Takashi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CATIONIC LIPOSOME CYTOSINE PHOSPHOROTHIOATE GUANINE OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; GLYCOPROTEIN P 15095; INTERLEUKIN 12; INTERLEUKIN 4; LIPOSOME; OLIGODEOXYNUCLEOTIDE DERIVATIVE; OVALBUMIN; TOLL LIKE RECEPTOR 9; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNMETHYLATED CYTOSINE PHOSPHOROTHIOATE GUANINE OLIGODEOXYNUCLEOTIDE;

ADJUVANT THERAPY; ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVATION; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; ENCAPSULATION; IMMUNITY; IMMUNOSTIMULATION; INTERFERON PRODUCTION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL CULTURE; TYPE 1 INNATE IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CPG ISLANDS; DENDRITIC CELLS; FEMALE; IMMUNITY, NATURAL; INTERFERON TYPE II; INTERLEUKIN-12; KILLER CELLS, NATURAL; LIPOSOMES; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDES; OVALBUMIN; T-LYMPHOCYTES; TH1 CELLS;

EID: 9244230628     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1691     Document Type: Article

References (63)

1. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer 2001;94:459-73.
2. Steinman RM. Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation. Mt Sinai J Med 2001;68:106-66.
3. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-46.
4. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:138-46.
5. Taniguchi M, Seino K, Nakayama T. The NKT cell system: bridging innate and acquired immunity. Nat Immunol 2003;4;1164-5.
6. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004;16:3-9.
7. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335-76.
8. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994;84:4008-27.
9. Kitamura H, Iwakabe K, Yahata T, et al. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 1999;189:1121-8.
10. + lymphoid dendritic cells. J Exp Med 1999;189:1981-6.
11. Liu YJ, Kadowaki N, Rissoan MC, Soumelis V. T cell activation and polarization by DC1 and DC2. Curr Top Microbiol Immunol 2000;251:149-59.
12. Dillon S, Agrawal A, Van Dyke T, et al. A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J Immunol 2004;172:4733-43.
13. Kodama T, Takeda K, Shimozato O, et al. Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. Eur J Immunol 1999;29:1390-6.
14. H2 bias of natural killer T cells. Nature 2001;413:531-4.
15. Hong S, Wilson MT, Serizawa I, et al. The natural killer T-cell ligand α-galactosyl-ceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001;7:1052-6.
16. Terabe M, Matsui S, Noben-Trauth N, et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000;1:515-20.
17. Smyth MJ, Godfrey DI. NKT cells and tumor immunity - a double-edged sword. Nat Immunol 2000;1:459-60.
18. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-γ-producing NKT response induced with α-galactosylceramide- loaded DCs. Nat Immunol 2002;3:867-74.
19. Nakui M, Ohta A, Sekimoto M, et al. Potentiation of antitumor effect of NKT cell ligand, α-galactosylceramide by combination with IL-12 on lung metastasis of malignant melanoma cells. Clin Exp Metastasis 2000;18:147-53.
20. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002;20:709-60.
21. Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol 1999;73:329-68.
22. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ. Proc Natl Acad Sci USA 1996;93:2879-83.
23. Krieg AM, Love-Homan L, Yi AK, Harty JT. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol 1998;161:2428-34.
24. Krieg AM, Wagner H. Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. Immunol Today 2000;21:521-6.
25. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-5.
26. Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, Wagner H. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002;32:1958-68.
27. Gursel I, Gursel M, Ishii KJ, Klinman DM. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol 2001;167:3324-8.
28. Kobayashi E, Motoki K, Uchida T, Fukushima H, Koezuka Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res 1995;7:529-34.
29. Chikh G, Schutze-Redelmeier MP. Liposomal delivery of CTL epitopes to dendritic cells. Biosci Rep 2002;22:339-53.
30. + T cells upon NKR-P1 cross-linking. J Exp Med 1996;183:2391-6.
31. Homung V, Rothenfusser S, Britsch S, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002;168:4531-7.
32. Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996;157:1840-5.
33. Sun S, Zhang X, Tough DF, Sprent J. Type 1 interferon-mediated stimulation of T cells by CpG DNA. J Exp Med 1998;188:2335-42.
34. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
35. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002;188:22-32.
36. Thurner B, Haendle I, Röder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669-78.
37. Lee KH, Wang E, Nielsen MB, et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 1999;163:6292-300.
38. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class 1 antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 1999;154:745-54.
39. Kobie JJ, Wu RS, Kurt RA, et al. Transforming growth factor β inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 2003;63:1860-4.
40. Hori S, Takahashi T, Sakaguchi S. Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv Immunol 2003;81:331-71.
41. Otsuji M, Kimura Y, Aoe T, Okamoto Y, Saito T. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 ζ chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci USA 1996;93:13119-24.
42. Nishimura T, Iwakabe K, Sekimoto M, et al. Distinct role of antigen-specific T helper type I (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 1999;190:617-27.
43. Chamoto K, Tsuji T, Funamoto H, et al. Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells. Cancer Res 2004;64:386-90.
44. Gyobu H, Tsuji T, Suzuki Y, et al. Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor. Cancer Res 2004;64:1490-5.
45. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
46. Nishimura T, Kitamura H, Iwakabe K, et al. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Int Immunol 2000;12:987-94.
47. Kitamura H, Ohta A, Sekimoto M, et al. α-Galactosylceramide induces early B-cell activation through IL-4 production by NKT cells. Cell Immunol 2000;199:37-42.
48. H2 development. Nat Immunol 2000;1:199-205.
49. Gould MP, Greene JA, Bhoj V, DeVecchio JL, Heinzel FP. Distinct modulatory effects of LPS and CpG on IL-18-dependent IFN-γ synthesis. J Immunol 2004;172:1754-62.
50. Amakata Y, Fujiyama Y, Andoh A, Hodohara K, Bamba T. Mechanism of NK cell activation induced by coculture with dendritic cells derived from peripheral blood monocytes. Clin Exp Immunol 2001;124:214-22.
51. Singh N, Hong S, Scherer DC, et al. Cutting edge: activation of NK T cells by CD1d and α-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J Immunol 1999;163:2373-7.
52. Munks MW, Mourich DV, Mittler RS, Weinberg AD, Hill AB. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine. Immunology 2004;112:559-66.
53. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003;3:609-20.
54. Davila E, Celis E. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol 2000;165:539-47.
55. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 1997;94:10833-7.
56. Davila E, Kennedy R, Celis E. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res 2003;63:3281-8.
57. Conant SB, Swanborg RH. Autoreactive T cells persist in rats protected against experimental autoimmune encephalomyelitis and can be activated through stimulation of innate immunity. J Immunol 2004;172:5322-8.
58. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CDS T cell memory. Science 2003;300:337-9.
59. Sun JC, Bevan MJ. Defective CDS T cell memory following acute infection without CD4 T cell help. Science 2003;300:339-42.
60. Kaech SM, Ahmed R. Immunology. CD8 T cells remember with a little help. Science 2003;300:263-5.
61. Heikenwalder M, Polymenidou M, Junt T, et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004;10:187-92.
62. Loisel S, Le Gall C, Doucet L, Ferec C, Floch V. Contribution of plasmid DNA to hepatotoxicity after systemic administration of lipoplexes. Hum Gene Ther 2001;12:685-96.
63. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004;4:249-58.